AmacaThera
PrivateLast Round
Series A
Extension
Nov 28, 2023
Total Funding Raised
$14.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AmacaThera operates in Healthcare & Life Sciences and is based in Toronto. Its latest recorded funding round was a Series A Extension round in November 2023.
AmacaThera is a biotechnology company that develops an injectable hydrogel platform for localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AmacaThera Comparables
Compare AmacaThera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Allay Therapeutics | 88% | |
| AiViva BioPharma | 84% | |
| InSitu Biologics, Inc. | 83% |
For institutional investors. Book with your work email.
AmacaThera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 28, 2023 | ||||
| Series A | Feb 22, 2021 | ||||
| Seed | Oct 3, 2019 |
For institutional investors. Book with your work email.
AmacaThera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Grey Sky Venture Partners | Seed |
| Inveready | Series A, Series A Extension |
| MaRS Discovery District | Series A, Series A Extension |
| BDC Capital | Series A, Series A Extension |
| Viva BioInnovator | Series A |
| Viva Biotech | Seed |
| Lumira Ventures | Seed, Series A Extension, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 2315% MoM, reaching 3.7K.
- Jun 26, 2026
Grew 27% QoQ from 15 to 19 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 3, 2026
AmacaThera Inc. partners with Merck Animal Health under a binding evaluation and option agreement to develop long-acting formulations for animal health in Canada on Apr 30th '25.
- licenses_technologyOct 6, 2026
AmacaThera Inc. entered into an exclusive worldwide licensing agreement with Pacira BioSciences, Inc. in Nov '25 for AMT-143, an investigational long-acting non-opioid anaesthetic, for up to $230m.
For institutional investors. Book with your work email.
AmacaThera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AmacaThera's valuation, stock price, and market status.
Is AmacaThera a public or private company?
AmacaThera is a private company.
What is the current stock price of AmacaThera?
AmacaThera is a private company, so its shares have no public market price. Caplight tracks AmacaThera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AmacaThera worth (valuation)?
Valuation information for AmacaThera is not publicly available.
Can I buy AmacaThera stock?
AmacaThera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AmacaThera's last funding round?
AmacaThera's most recent funding round was Series A Extension on November 28, 2023.
Who are the main investors in AmacaThera?
Key investors in AmacaThera include Viva Biotech, Lumira Ventures, Sprout BioVentures.
Will AmacaThera IPO soon?
No public IPO plans have been announced for AmacaThera.
How can I track AmacaThera secondary market activity?
Caplight tracks bids, offers, and trades in AmacaThera's shares on secondary markets.